Filing Details

Accession Number:
0001714899-23-000023
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-13 19:14:01
Reporting Period:
2023-02-09
Accepted Time:
2023-02-13 19:14:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724310 J. Ryan Watts C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-09 3,433 $30.59 2,229,031 No 4 S Indirect See footnote
Common Stock Acquisiton 2023-02-10 25,000 $0.68 2,254,031 No 4 M Indirect See footnote
Common Stock Disposition 2023-02-10 25,000 $29.10 2,229,031 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 M Indirect See footnote
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-02-10 25,000 $0.00 25,000 $0.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,220,617 2025-08-20 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 208,134 Direct
Footnotes
  1. Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.39 to $30.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8,800 restricted stock units held by the Reporting Person
  4. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
  5. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
  6. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.75 to $29.57 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  7. Includes 208,134 RSUs.
  8. The vesting of the shares subject to the option is contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on the date the closing price of Issuer's Common Stock equaled or exceeded $40.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018; and 50% of the shares subject to the option vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days, beginning no earlier than June 10, 2018.